<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205812</url>
  </required_header>
  <id_info>
    <org_study_id>INCMGA 0012-304</org_study_id>
    <nct_id>NCT04205812</nct_id>
  </id_info>
  <brief_title>Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)</brief_title>
  <official_title>A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zai Lab (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy
      with or without INCMGA00012 in participants with metastatic squamous and nonsquamous
      non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 4.5 years.</time_frame>
    <description>Defined as the time from randomization until death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approximately 4.5 years.</time_frame>
    <description>Defined as the time from randomization until disease progression by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as determined by blinded independent central review (BICR) or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 4.5 years.</time_frame>
    <description>Defined as the proportion of participants who have a confirmed complete response or partial response per RECIST v1.1 based on BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately 4.5 years.</time_frame>
    <description>Defined as the time from the earliest date of documented response until earliest date of disease progression (per RECIST v1.1 based on BICR) or death from any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events</measure>
    <time_frame>Approximately 4.5 years.</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment up to 90 days after last dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of INCMGA00012 when administered with chemotherapy</measure>
    <time_frame>Approximately 4.5 years.</time_frame>
    <description>Maximum observed plasma or serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of INCMGA00012 when administered with chemotherapy</measure>
    <time_frame>Up to approximately 4.5 years.</time_frame>
    <description>Area under the plasma or serum concentration curve.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">530</enrollment>
  <condition>Metastatic Squamous Non-Small Cell Lung Cancer</condition>
  <condition>Metastatic Nonsquamous Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>INCMGA00012 + chemotherapy (nonsquamous NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCMGA00012 with pemetrexed + cisplatin OR carboplatin followed by INCMGA00012 plus pemetrexed until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + chemotherapy (nonsquamous NSCLC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo with pemetrexed + cisplatin OR carboplatin followed by placebo plus pemetrexed until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCMGA00012 + chemotherapy (squamous NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCMGA00012 with carboplatin + paclitaxel OR nab-paclitaxel followed by INCMGA00012 until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + chemotherapy (squamous NSCLC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo with carboplatin + paclitaxel OR nab-paclitaxel followed by placebo until progression. Participants assigned to placebo + chemotherapy will have the option of receiving open-label monotherapy INCMGA00012 in a crossover period after documentation of progressive disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retifanlimab</intervention_name>
    <description>INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.</description>
    <arm_group_label>INCMGA00012 + chemotherapy (nonsquamous NSCLC)</arm_group_label>
    <arm_group_label>INCMGA00012 + chemotherapy (squamous NSCLC)</arm_group_label>
    <other_name>INCMGA00012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.</description>
    <arm_group_label>Placebo + chemotherapy (nonsquamous NSCLC)</arm_group_label>
    <arm_group_label>Placebo + chemotherapy (squamous NSCLC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.</description>
    <arm_group_label>INCMGA00012 + chemotherapy (nonsquamous NSCLC)</arm_group_label>
    <arm_group_label>Placebo + chemotherapy (nonsquamous NSCLC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.</description>
    <arm_group_label>INCMGA00012 + chemotherapy (nonsquamous NSCLC)</arm_group_label>
    <arm_group_label>Placebo + chemotherapy (nonsquamous NSCLC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.</description>
    <arm_group_label>INCMGA00012 + chemotherapy (nonsquamous NSCLC)</arm_group_label>
    <arm_group_label>INCMGA00012 + chemotherapy (squamous NSCLC)</arm_group_label>
    <arm_group_label>Placebo + chemotherapy (nonsquamous NSCLC)</arm_group_label>
    <arm_group_label>Placebo + chemotherapy (squamous NSCLC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.</description>
    <arm_group_label>INCMGA00012 + chemotherapy (squamous NSCLC)</arm_group_label>
    <arm_group_label>Placebo + chemotherapy (squamous NSCLC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel</intervention_name>
    <description>nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.</description>
    <arm_group_label>INCMGA00012 + chemotherapy (squamous NSCLC)</arm_group_label>
    <arm_group_label>Placebo + chemotherapy (squamous NSCLC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed NSCLC (either nonsquamous or squamous) that
             is Stage IV (AJCC v8).

          -  No prior systemic treatment for the advanced/metastatic NSCLC

          -  Able to provide a formalin-fixed archival tumor tissue sample during screening, or a
             fresh tumor biopsy

          -  Measurable disease per RECIST v1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Life expectancy of at least 3 months.

          -  Willingness to avoid pregnancy or fathering children.

          -  Adequate organ function as indicated by protocol-specified laboratory values.

        Exclusion Criteria:

          -  Clinically significant cardiac disease within 6 months of start of study treatment.

          -  Any major surgery within 3 weeks of the first dose of study treatment.

          -  Thoracic radiation therapy of &gt; 30 Gy within 6 months of the first dose of study
             treatment.

          -  History of peripheral neuropathy ≥ Grade 2 CTCAE v5 for participants who may receive
             cisplatin, paclitaxel, or nab-paclitaxel.

          -  Untreated central nervous system metastases and/or carcinomatous meningitis.

          -  Evidence or history of interstitial lung disease or noninfectious pneumonitis that
             required systemic steroids.

          -  Active infection requiring systemic therapy or active tuberculosis.

          -  Superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical
             cancer, or other in situ cancers.

          -  Has contraindications to chemotherapy agents used in the study.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years.

          -  Is receiving systemic antibiotics or steroid therapy ≤ 7 days prior to the first dose
             of study treatment.

          -  Has received a live vaccine within 30 days before the first dose of study treatment
             (and until 90 days after last dose of study drug).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Incyte Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>July 11, 2020</last_update_submitted>
  <last_update_submitted_qc>July 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>nonsquamous</keyword>
  <keyword>squamous</keyword>
  <keyword>PD-1</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

